Futura Medical PLC
04 March 2008
For immediate release 4 March 2008
Futura Medical plc
Notification of Preliminary Results
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative
products for consumer healthcare, informs the London Stock Exchange that their
preliminary results for the year ended 31 December 2007 will be announced on
Thursday 13 March 2008.
For further information:
Futura Medical plc
James Barder, Chief Executive Tel: +44 (0) 1483 685 670
mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk
Media enquiries:
Buchanan Communications
Mark Court / Rebecca Skye Dietrich Tel: +44 (0) 20 7466 5000
Nominated Adviser:
Canaccord Adams Limited
Mark Williams / Erin Needra Tel: +44 (0) 20 7050 6500
Notes
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for
consumer healthcare. The Company is developing a portfolio of products and its
strategy is to license their manufacture and distribution to major
pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.
www.futuramedical.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.